NPCE - NASDAQ

NeuroPace, Inc.

NPCE·NASDAQ

$15.88

-2.5%

HealthcareMedical - Devices

NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$541.41M

EPS-0.6600

P/E Ratio-24.06

Earnings Date08/11/2026

105.56M

Assets

12%

3Y-7.0%

5Y+89.0%

10Y+400.0%

86.53M

Total Liabilities

3Y+9.0%

5Y-58.0%

10Y-42.0%

19.03M

Total Equity

138%

3Y-45.0%

5Y-113.0%

10Y-115.0%

NeuroPace, Inc. Funding & Solvency Profile

NPCE · NASDAQ

Current Assets

Cash & Cash Equivalents21.69M

Net Receivables14.68M

Inventory16.90M

Other Current Assets1.44M

Total Current Assets94 M

Non-Current Assets

Property, Plant & Equipment11.26M

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets235.00K

Total Non-Current Assets11 M

Total Assets

105.56M

Financial Health Analysis

Current Ratio

5.28x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

4.55x

High financial leverage. Heavy reliance on debt may indicate increased financial risk and potential solvency concerns.

Working Capital

76 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

89% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Mixed signals: Strong short-term liquidity provides comfort, but high overall leverage requires careful monitoring of debt servicing capabilities and refinancing risk.

NeuroPace, Inc. Balance Sheet

NPCE • NASDAQ

NeuroPace, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	21.7M	13.4M	18.1M	6.6M	19.2M	26.4M	4.1M
Short-Term Investments	39.4M	39.3M	48.4M	70.8M	96.4M	11.7M	969K
Cash & Short-Term Investments	61.1M	52.8M	66.5M	77.4M	115.6M	38.1M	5.1M
Net Receivables	14.7M	12.9M	12.3M	7.5M	7.1M	8.4M	6M
Accounts Receivables	14.7M	12.9M	12.3M	7.5M	7.1M	8.4M	6M
Inventory	16.9M	13.4M	11.2M	9.7M	7.8M	6.9M	7.9M
Prepaids	0.0	0.0	0.0	0.0	2.3M	1.2M	1.3M
Other Current Assets	1.4M	2.4M	2.7M	3.1M	0.0	0.0	0.0
Total Current Assets	94.1M	81.3M	92.7M	97.7M	132.8M	54.6M	20.3M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	11.3M	12.9M	14.4M	15.9M	603K	515K	810K
Other Non-Current Assets	235K	413K	524K	490K	143K	873K	25K
Total Non-Current Assets	11.5M	13.3M	14.9M	16.4M	746K	1.4M	835K
Total Assets	105.6M	94.6M	107.7M	114.1M	133.6M	56M	21.1M
LIABILITIES
CURRENT LIABILITIES
Total Payables	2.2M	3M	2.3M	2.1M	1.4M	949K	903K
Accounts Payable	2.2M	3M	2.3M	2.1M	1.4M	949K	903K
Accrued Expenses	0.0	9.8M	11.2M	7.4M	7.4M	5.9M	3.7M
Short Term Debt	2.1M	0.0	0.0	0.0	0.0	2M	62.8M
Capital Lease Obligations (Current)	0.0	1.9M	1.6M	1.4M	0.0	0.0	0.0
Deferred Revenue	141K	555K	1.1M	0.0	0.0	0.0	6.7M
Other Current Liabilities	13.3M	0.0	0.0	0.0	490K	666K	1M
Total Current Liabilities	17.8M	15.2M	16.2M	11M	9.3M	9.6M	75.1M
NON-CURRENT LIABILITIES
Long Term Debt	68.7M	59.5M	57M	52.9M	49.8M	50.8M	0.0
Other Non-Current Liabilities	0.0	0.0	0.0	0.0	911K	143.4M	75.3M
Total Non-Current Liabilities	68.7M	71.5M	70.8M	68.4M	50.8M	194.2M	75.3M
Capital Lease Obligations	0.0	13.8M	15.4M	16.9M	0.0	0.0	0.0
Total Liabilities	86.5M	86.6M	87M	79.3M	60.1M	203.8M	150.4M
SHAREHOLDERS' EQUITY
Treasury Stock	0.0	0.0	0.0	0.0	0.0	0.0	-73.6M
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	73.6M
Common Stock	34K	30K	28K	25K	24K	0.0	1K
Additional Paid-In Capital	571.4M	538.9M	524.4M	506.7M	497.5M	239.8M	234.3M
Retained Earnings	-552.4M	-531M	-503.8M	-470.9M	-423.8M	-387.7M	-363.6M
Accumulated Other Comprehensive Income/Loss	0.0	0.0	0.0	-1.1M	-272K	33K	1K
Total Stockholders' Equity	19M	8M	20.7M	34.8M	73.5M	-147.8M	-129.4M
Total Equity	19M	8M	20.7M	34.8M	73.5M	-147.8M	-129.4M
SUMMARY
Total Liabilities & Equity	105.6M	94.6M	107.7M	114.1M	133.6M	56M	21.1M
Total Investments	39.4M	39.3M	48.4M	70.8M	96.4M	11.7M	969K
Total Debt	70.8M	73.3M	72.4M	69.8M	49.8M	52.9M	62.8M
Net Debt	49.1M	59.9M	54.3M	63.2M	30.7M	26.5M	58.7M
Shares Outstanding	33,304,106	33,304,106	33,304,106	33,304,106	33,304,106	33,304,106	33,304,106

SEC Filings

NPCE - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 12, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 12, 2026	March 31, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 21, 2026	June 05, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 03, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 03, 2026	March 03, 2026	2026	View Filing
8-K 8-K 2025 N/A	November 04, 2025	November 04, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	November 04, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	August 12, 2025	August 12, 2025	2025	View Filing
10-Q 10-Q 2025 Q2 Q2	August 12, 2025	June 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	June 24, 2025	June 20, 2025	2025	View Filing

Showing 1 to 10 of 76 filings

Related Guides

Blog Categories

Continue your NPCE research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.